Clinical

The Anti-Obesity Potential of Cirpusins® Containing Piceatannol, Scirpusin A, and Scirpusin B from Rhizomes: Preclinical and Clinical Evaluations
Objective and Study Design

A pilot, single-center, randomized, double-blind, parallel-group, placebo-controlled study was conducted to assess the efficacy, safety, and tolerability of Cirpusins® in 30 obese individuals for 90 days.

Dosage

Subjects were administered Cirpusins® capsule (525 mg) or placebo 30 minutes before food twice a day.

Results
  • A statistically significant reduction in body weight, body mass index, and waist circumference was observed in Cirpusins® group compared with placebo after 90 days
  • Significant improvement was seen in serum lipid profiles like total cholesterol, triglycerides, LDL, VLDL and HDL cholesterol levels
  • Moreover, Cirpusins® was found to be safe and well-tolerated by all the subjects (Figure 3)
Conclusion

Clinical study showed that Cirpusins® is potent and safe health adjuvant for managing hypercholesterolemia and obesity in human subjects.

Figure 3: Health benefits of Cirpusins® as observed in the clinical study

Continue Reading: doi.org/10.2147/DMSO.S348412